AIM ImmunoTech (AIM) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 01, 2014
Document and Entity Information	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'
Entity Registrant Name	'HEMISPHERX BIOPHARMA INC	'
Entity Central Index Key	'0000946644	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding (shares)	'	200,027,874

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$1,262	$803
Marketable securities	16,169	17,391
Prepaid expenses and other current assets	235	358
Total current assets	17,666	18,552
Property and equipment, net	4,716	5,053
Patent and trademark rights, net	853	1,080
Construction in progress	7,269	7,046
Other assets	134	136
Total assets	30,638	31,867
Current liabilities:	'	'
Accounts payable	2,447	1,271
Accrued expenses	1,781	1,228
Current portion of capital lease	29	33
Total current liabilities	4,257	2,532
Long-term liabilities	'	'
Long-term portion of capital lease	3	23
Redeemable warrants	13	14
Total liabilities	4,273	2,569
Commitments and contingencies (Notes 6, 8, 10)	'	'
Stockholders’ equity:	'	'
Preferred stock, par value $0.01 per share, authorized 5,000,000; issued and outstanding; none	0	0
Common stock, par value $0.001 per share, authorized 350,000,000 shares; issued and outstanding 193,708,424 and 168,660,370, respectively	194	168
Additional paid-in capital	299,598	289,563
Accumulated other comprehensive loss	-114	-114
Accumulated deficit	-273,313	-260,319
Total stockholders’ equity	26,365	29,298
Total liabilities and stockholders’ equity	$30,638	$31,867

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value per share (usd per share)	$0.01	$0.01
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (usd per share)	$0.00	$0.00
Common stock, authorized shares	350,000,000	350,000,000
Common stock, issued	193,708,424	168,660,370
Common stock, outstanding	193,708,424	168,660,370

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Clinical treatment programs	$45	$36	$157	$114
Total revenues	45	36	157	114
Costs and expenses:	'	'	'	'
Production/cost of goods sold	306	252	923	1,078
Research and development	1,894	2,173	6,550	6,827
General and administrative	2,174	2,070	7,210	5,964
Total costs and expenses	4,374	4,495	14,683	13,869
Operating loss	-4,329	-4,459	-14,526	-13,755
Interest expense	-3	-4	-9	-14
Interest and other income	130	89	414	624
Other than temporary impairment loss on marketable securities	0	-800	0	-800
Gain from sale of income tax net operating losses	0	0	1,126	686
Redeemable warrants valuation adjustment	0	38	1	229
Net loss	-4,202	-5,136	-12,994	-13,030
Other Comprehensive Income (Loss):	'	'	'	'
Unrealized gain (loss) on marketable securities	-169	197	0	-848
Reclassification adjustments for impairment losses included in net loss	0	800	0	800
Net comprehensive loss	($4,371)	($4,139)	($12,994)	($13,078)
Basic and diluted loss per share (usd per share)	($0.02)	($0.03)	($0.07)	($0.08)
Weighted average shares outstanding, basic and diluted (shares)	190,677,576	167,389,685	184,434,475	167,135,111

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2013	$29,298	$168	$289,563	($114)	($260,319)
Balance, Common Stock (Shares) at Dec. 31, 2013	'	168,660,370	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Stock issued for settlement of accounts payable, Common Stock (Shares)	'	153,273	'	'	'
Stock issued for settlement of accounts payable	38	'	38	'	'
Equity-based compensation	260	'	260	'	'
Stock sold at the market (shares)	'	24,894,781	'	'	'
Stock sold at the market	9,763	26	9,737	'	'
Net comprehensive loss	-12,994	'	'	'	-12,994
Balance at Sep. 30, 2014	$26,365	$194	$299,598	($114)	($273,313)
Balance, Common Stock (Shares) at Sep. 30, 2014	'	193,708,424	'	'	'

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Stockholders' Equity [Abstract]	'	'
Common stock, par value (usd per share)	$0.00	$0.00

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($12,994)	($13,030)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of property and equipment	500	504
Amortization and abandonment of patent and trademark rights	414	144
Redeemable warrants valuation adjustment	-1	-229
Equity-based compensation	260	292
Change in assets and liabilities:	'	'
Inventories	0	453
Prepaid expenses and other current assets	123	-10
Accounts payable	1,214	-197
Accrued expenses	553	-1,573
Net cash used in operating activities	-9,931	-13,646
Cash flows from investing activities:	'	'
Purchase of property, equipment and construction in progress	-386	-747
Additions to patent and trademark rights	-187	-184
Deposits on capital leases refunded	2	3
Deposit paid on office lease	0	-74
Maturities of short-term and long-term marketable securities	1,222	14,070
Net cash provided by investing activities	651	13,068
Cash flows from financing activities:	'	'
Payments on capital leases	-24	-36
Proceeds from sale of stock, net of issuance costs	9,763	0
Net cash provided by (used in) financing activities	9,739	-36
Net increase (decrease) in cash and cash equivalents	459	-614
Cash and cash equivalents at beginning of period	803	2,212
Cash and cash equivalents at end of period	1,262	1,598
Supplemental disclosures of non-cash investing and financing cash flow information:	'	'
Issuance of common stock for accounts payable	38	237
Unrealized loss on marketable securities	0	-93
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest expense and capitalized construction interest	($9)	($144)

Basis_Of_Presentation

Basis Of Presentation	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis Of Presentation	'
	Basis Of Presentation
	The consolidated financial statements include the financial statements of Hemispherx Biopharma, Inc. and its wholly-owned subsidiaries. The Company has three domestic subsidiaries: BioPro Corp., BioAegean Corp. and Core Biotech Corp., all of which are incorporated in Delaware and are dormant. The Company’s foreign subsidiary, Hemispherx Biopharma Europe N.V./S.A., established in Belgium in 1998, has minimal activity. All significant intercompany balances and transactions have been eliminated in consolidation. Certain items in these financial statements have been reclassified to conform to the current year presentation.
	In the opinion of Management, all adjustments necessary for a fair presentation of such consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year.
	The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto.
	These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2013 and 2012, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	Net Loss Per Share
	Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 58,129,967 and 38,421,415 shares for the nine months ended September 30, 2014 and 2013, respectively, are excluded from the calculation of diluted net loss per share since their effect is anti-dilutive.

EquityBased_Compensation

Equity-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Equity-Based Compensation	'
	Equity-Based Compensation
	The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. There were 955,000 options or equity warrants granted in the nine months ended September 30, 2014. The fair values of the options and equity warrants granted in the nine months ended September 30, 2014 and 2013, were estimated based on the following weighted average assumptions:
		Nine Months Ended September 30,
		2014		2013
	Risk-free interest rate	1.66% - 1.72%		0.14% - 1.40%
	Expected dividend yield	—		—
	Expected lives	5 years		1 year to 5 years
	Expected volatility	88.33% - 92.63%		89.73% - 118.22%
	Weighted average grant date fair value for options and equity warrants issued	$0.22 per option/warrant for 955,000 options/warrants		$0.14 per option/warrant for 3,870,000 options/warrants
	Stock option for employees' activity during the nine months ended September 30, 2014 is as follows:
	Stock option activity for employees:
		Number of			Weighted		Weighted	Aggregate
		Options			Average		Average	Intrinsic
					Exercise		Remaining	Value
					Price		Contractual
							Term
							(Years)
	Outstanding January 1, 2014	10,611,480			$	1.73	4.92	$	—
	Granted	905,000			0.36		9.67	—
	Forfeited	(367,000	)		1.42		4.22	—
	Outstanding September 30, 2014	11,149,480			$	1.63	4.61	$	—
	Vested and expected to vest September 30, 2014	11,149,480			$	1.63	4.61	$	—
	Exercisable September 30, 2014	10,541,980			$	1.69	4.2	$	—
	905,000 options to purchase shares were granted to employees during the nine months ended September 30, 2014.
	Unvested stock option activity for employees:
		Number of			Weighted		Average		Aggregate
		Options			Average		Remaining		Intrinsic
					Exercise		Contractual		Value
					Price		Term
							(Years)
	Outstanding January 1, 2014	525,000			$	0.29	8.38		$	—
	Granted	905,000			0.36		9.67		—
	Vested	(822,500	)		0.3		9.14		—
	Forfeited	—			—		—		—
	Outstanding September 30, 2014	607,500			$	0.37	8.63		$	—
	Stock option activity for non-employees:
		Number of			Weighted		Weighted		Aggregate
		Options			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term (Years)
	Outstanding January 1, 2014	4,128,432			$	1.48	5.01		$	—
	Granted	50,000			2.6		9.17		—
	Exercised	—			—		—		—
	Forfeited	(368,428	)		2.8		1.93		—
	Outstanding September 30, 2014	3,810,004			$	1.37	4.64		$	—
	Vested and expected to vest September 30, 2014	3,810,004			$	1.37	4.64		$	—
	Exercisable September 30, 2014	3,743,337			$	1.58	4.44		$	—
	50,000 options to purchase shares were granted to non-employees during the nine months ended September 30, 2014.
	Unvested stock option activity for non-employees during the year:
		Number of			Weighted		Weighted		Aggregate
		Options			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term
							(Years)
	Outstanding January 1, 2014	470,833			$	0.25	9.61		$	—
	Options granted	50,000			2.6		9.17		—
	Options vested	(454,166	)		0.28		8.86		—
	Options forfeited	—			—		—		—
	Outstanding September 30, 2014	66,667			$	1.84	9.09		$	—
	The impact on the Company’s results of operations of recording equity-based compensation for the nine months ended September 30, 2014 and 2013 was to increase general and administrative expenses by approximately $260,000 and $292,000, respectively. There was no impact on basic and fully diluted earnings per share for the nine months ended September 30, 2014 and 2013.
	As of September 30, 2014 and 2013, respectively, there was $301,000 and $492,000 of unrecognized equity-based compensation cost related to options granted under the Equity Incentive Plan.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	The Company uses the lower of first-in, first-out (“FIFO”) cost or market method of accounting for inventory.
	Inventories consist of the following:	(in thousands)
		September 30,		December 31,
		2014		2013
	Inventory work-in-process, January 1	$	—	$	453
	Production	—		5
	Spoilage	—		(458		)
	Inventory work-in-process, end of period	$	—	$	—
	In April 2012, FDA reviewers raised certain questions about the status of our existing lots of older Work-In-Process Alferon® materials and Alferon® Active Pharmaceutical Ingredient (“API”), which would need to be released by the FDA before those materials could be used in commercial product. After conducting all of the appropriate tests on samples of the inventory during 2013, the Company concluded that it could not alleviate certain questions the FDA had about the older Work-In-Process Alferon N Injection®. Accordingly, these lots were not be submitted to the FDA to request release for commercial sale and their remaining dollar value was written-off in 2013.

Marketable_Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Marketable Securities	'
	Marketable Securities
	Marketable securities consist of equity securities. As of September 30, 2014, it was determined that none of the marketable securities had other-than-temporary impairments. At September 30, 2014, all securities were classified as available for sale investments and were measured as Level 1 instruments of the fair value measurements standard (see "Note 10: Fair Value").
	Securities classified as available for sale consisted of:
	30-Sep-14
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair Value			Short-Term			Long Term
		Cost			Unrealized			Unrealized							Investments			Investments
					Gains			Losses
	Mutual Funds	$	16,283		$	—		$	(114	)		$	16,169		$	16,169		$	—
	Totals	$	16,283		$	—		$	(114	)		$	16,169		$	16,169		$	—
	31-Dec-13
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair Value			Short-Term			Long Term
		Cost			Unrealized			Unrealized							Investments			Investments
					Gains			Losses
	Mutual Funds	$	17,505		$	115		$	(229	)		$	17,391		$	17,391		$	—
	Totals	$	17,505		$	115		$	(229	)		$	17,391		$	17,391		$	—
	Unrealized losses on investments
	Investments with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows:
	30-Sep-14
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number		Values			Losses				Values			Losses			Fair			Unrealized
		in loss															Value			Losses
		position
	Mutual Funds	1		$	9,630		$	(126	)		$	—		$	—		$	9,630		$	(126	)
	Totals	1		$	9,630		$	(126	)		$	—		$	—		$	9,630		$	(126	)
	31-Dec-13
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number		Values			Losses				Values			Losses			Fair			Unrealized
		in loss															Value			Losses
		position
	Mutual Funds	1		$	12,460		$	(229	)		$	—		$	—		$	12,460		$	(229	)
	Totals	1		$	12,460		$	(229	)		$	—		$	—		$	12,460		$	(229	)

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	Accrued Expenses
	Accrued expenses consist of the following:
		(in thousands)
		September 30,		December 31,
		2014		2013
	Compensation	$	1,438	$	378
	Professional fees	141		270
	Other expenses	192		529
	Accrued Alferon production costs	10		51
		$	1,781	$	1,228

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]	'
Property and Equipment	'
	Property and Equipment
		(in thousands)
		September 30,			December 31,
		2014			2013
	Land, buildings and improvements	$	4,209		$	4,209
	Furniture, fixtures, and equipment	5,256			5,093
	Leasehold improvements	85			85
	Total property and equipment	9,550			9,387
	Less: accumulated depreciation and amortization	(4,834		)	(4,334		)
	Property and equipment, net	$	4,716		$	5,053
	Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from five to thirty-nine years.
	Construction in progress consists of funds used for the construction and installation of property and equipment within the Company's New Brunswick, NJ facility. As of September 30, 2014, construction in progress is reported as $7,269,000 as compared to $7,046,000 as of December 31, 2013. The Company capitalized $143,000 of interest charges through December 31, 2013 related to the construction in progress.

Margin_Account_Loan

Margin Account Loan	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Margin Account Loan	'
	Margin Account Loan
	A “Margin Account” loan was established with Wells Fargo Advisors for which the proceeds of this flexible form of indebtedness effectively serves the Company as a line of credit to finance the capital improvement project underway at the New Brunswick, New Jersey Manufacturing facility. In order to maintain this Margin Account, established on July 26, 2011, the Company needs to pledge, restrict from sale and segregate to a dedicated Margin Account its marketable securities at an approximate ratio of two to one of security collateral to debt undertaken. With the exception of collateral requirements, the Company maintains all the rights and benefits of ownership including receipt of interest, dividends or proceeds from the securities. While this Margin Account has no material establishment or maintenance fees, it currently carries an effective interest rate of approximately 2.5% per annum applied against the “Margin Debit Balance” (i.e., those funds withdrawn and outstanding), based on the prevailing “Wells Fargo Base Rate” less 2.75%. As of September 30, 2014 and December 31, 2013, the principal loan balance of the Margin Account was $0. For the year ended December 31, 2013, the interest charge was approximately $130,000 which has been capitalized along with the other costs related to the capital improvement project.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	The Equity Incentive Plan of 2009, effective June 24, 2009, authorizes the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock and other stock awards. A maximum of 15,000,000 shares of common stock is reserved for potential issuance pursuant to awards under the Equity Incentive Plan of 2009. Unless sooner terminated, the Equity Incentive Plan of 2009 will continue in effect for a period of 10 years from its effective date. For the nine months ended September 30, 2014, the Company issued 905,000 options to some employees to purchase shares of common stock.
	On July 23, 2012, the Company entered into a new Equity Distribution Agreement (the “New EDA”) with Maxim pursuant to which the Company may sell up to $75,000,000 worth of its shares of Common Stock from time to time through Maxim, as sales agent. Under the New EDA, Maxim is entitled to a fixed commission rate of 4.0% of the gross sales price of Shares sold under the New EDA, up to aggregate gross proceeds of $10,000,000, and thereafter, at a fixed commission rate of 3.0% of the gross sales price of Shares sold under the New EDA. Sales of the Shares, if any, may be made in transactions that are deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers' transactions, including on the NYSE MKT, at market prices or as otherwise agreed with Maxim. The Company has no obligation to sell any of the Shares and may at any time suspend offers under the New EDA or terminate the New EDA. The Shares are being sold pursuant to the Company's Universal Shelf Registration Statement on Form S-3, declared effective by the Securities and Exchange Commission on July 2, 2012. On September 14, 2012, the Company filed a Prospectus Supplement with the SEC increasing the number of shares covered by the Prospectus from 12,000,000 to 20,000,000 shares under the New EDA. On October 5, 2012, the Company filed an updated Prospectus Supplement increasing the number of shares covered by the Prospectus to 40,000,000 shares to be allocated for public sale under the Prospectus Supplement pursuant to the New EDA. On December 23, 2013, the Company filed an updated Prospectus Supplement with the Securities and Exchange Commission to revise the New EDA for an aggregate of 90,000,000 shares to be allocated for public sale under the Prospectus Supplement pursuant to the New EDA.
	For the nine months ended September 30, 2014, the Company had sold 24,894,781 shares of the New EDA that resulted in net cash proceeds of approximately $9,763,000 after direct expenses along with commissions paid to Maxim for approximately $302,000.
	The Company plans to use the net proceeds from the offering as follows: (1) Costs to upgrade the Alferon N Injection® manufacturing facility and to prepare for the FDA pre-approval inspections, (2) Potential new preclinical or clinical studies in order to gain commercial approval for Ampligen® and broader approvals for Alferon® and Alferon LDO®, (3) Working capital to build and maintain sufficient inventory by procuring raw materials, supplies and other items for the New Brunswick manufacturing facility, as well as to remunerate outside contractors for necessary services, such as, final filling and finishing operations in order to meet any anticipated demand from normal operations as well as through the possible pursuit of other disease areas and/or geographic regions that may present themselves, (4) Pursuit of potential partnering opportunities for Ampligen®, (5) Potential establishment of sales and marketing capabilities, as well as consideration towards the expansion of the Company’s manufacturing capacity.

Fair_Value

Fair Value	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value	'
	Fair Value
	The Company is required under U.S. Generally Accepted Accounting Principles (“GAAP”) to disclose information about the fair value of all the Company’s financial instruments, whether or not these instruments are measured at fair value on the Company’s Consolidated Balance Sheets.
	The Company estimates that the fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to the short-term maturities of these items.
	The Company also has certain warrants with a cash settlement feature in the unlikely occurrence of a Fundamental Transaction. The fair value recalculation of the Liability resulting from the issuance of the Warrants ("Call") and existence of the Fundamental Transaction ("Put") related to the May 2009 issuance, are calculated using a Monte Carlo Simulation. While the Monte Carlo Simulation is one of a number of possible pricing models, the Company has determined it to be industry accepted and fairly presented the Fair Value of the Warrants. As an additional factor to determine the Fair Value of the Put's Liability, the occurrence probability of a Fundamental Transaction event was factored into the valuation. The Company recomputes the fair value of the Warrants at the end of each quarterly reporting period. Such value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions or the numbers input based on such assumptions, the resulting fair value could be materially different. The remaining redeemable warrants expire in November 2014 and there was no change in the assumptions utilized to estimate the fair value as of September 30, 2014. The balance of the redeemable warrants was approximately $13,000 and $14,000 as of September 30, 2014 and December 31, 2013, respectively.
	Fair value at September 30, 2014, was estimated using the following assumptions:
	Underlying price per share	$0.19 - $0.27
	Exercise price per share	$1.31 - $1.65
	Risk-free interest rate	0.06% - 0.23%
	Expected holding period	0.38 - 1.64 yrs.
	Expected volatility	69.74% - 113.56%
	Expected dividend yield	None
	While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the numbers input may change from period to period (e.g., the actual historical prices input for the relevant period). The carrying amount and estimated fair value of the above warrants was approximately $13,000 and $14,000 at September 30, 2014 and December 31, 2013, respectively. There were no other financial instruments at September 30, 2014.
	On January 1, 2008, the Company adopted new accounting guidance (codified at FASB ASC 820 and formerly Statement No. 157 Fair Value Measurements) that defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. The guidance does not impose any new requirements around which assets and liabilities are to be measured at fair value, and instead applies to asset and liability balances required or permitted to be measured at fair value under existing accounting pronouncements. The Company measures its warrant liability for those warrants with a cash settlement feature at fair value. As of September 30, 2014, the Company had no other derivative assets or liabilities.
	FASB ASC 820-10-35-37 (formerly SFAS No. 157) establishes a valuation hierarchy based on the transparency of inputs used in the valuation of an asset or liability. Classification is based on the lowest level of inputs that is significant to the fair value measurement. The valuation hierarchy contains three levels:
	•	Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market.
	•	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market.
	•	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.
	As of September 30, 2014 and 2013, the Company has classified the Warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing these Warrants.
	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as of September 30, 2014:
		(in thousands)
		Total			Level 1			Level 2		Level 3
	Assets:
	Marketable Securities	$	16,169		$	16,169		$	—	$	—
	Liabilities:
	Warrants	$	(13	)	$	—		$	—	$	(13	)
	The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows:
		Fair Value of Redeemable
		Warrants
		(in thousands)
		2014			2013
	Balance at January 1	$	14		$	295
	Fair value adjustment at March 31	—			(89		)
	Balance at March 31	14			206
	Fair value adjustment at June 30	(1		)	(102		)
	Balance at June 30	13			104
	Fair value adjustment at September 30	—			(38		)
	Balance at September 30	$	13		$	66

Cash_And_Cash_Equivalents

Cash And Cash Equivalents	9 Months Ended
	Sep. 30, 2014
Cash and Cash Equivalents, at Carrying Value [Abstract]	'
Cash And Cash Equivalents	'
	Cash And Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In 2014,  the FASB issued Accounting Standards Updates (“ASU”) 2014-1 through 2014-15. These updates did not have a significant impact on the financial statements.

Funds_Received_From_Sale_Of_In

Funds Received From Sale Of Income Tax Net Operating Losses	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Funds Received From Sale Of Income Tax Net Operating Losses	'
	Funds Received From Sale Of Income Tax Net Operating Losses
	As of December 31, 2013, the Company has approximately $134,000,000 of federal net operating loss carryforwards (expiring in the years 2018 through 2033) available to off-set future federal taxable income. The Company also had approximately $37,000,000 of Pennsylvania state net operating loss carryforwards (expiring in the years 2019 through 2033) and approximately $25,000,000 of New Jersey state net operating loss carryforwards (expiring in the years 2019 through 2020) available to off-set future state taxable income.
	In February 2014, the Company effectively sold $13,900,000 of its approximately $25,000,000 of New Jersey state net operating loss carryforwards (for the year 2012) for approximately $1,126,000. The utilization of certain state net operating loss carry-forwards may be subject to annual limitations. With no tax due for the foreseeable future, the Company has determined that the accounting for interest or penalties related to the payment of tax is not necessary at this time.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	The Company evaluated subsequent events through the date on which these financial statements were issued and determined that no subsequent event constituted a matter that required adjustment to the financial statements for the nine months ended September 30, 2014.
	In October 2014, the Company entered into a purchase commitment with a contract manufacturer for approximately $700,000 for the manufacture of clinical batches of Ampligen®.

Net_Loss_Per_Share_Net_Loss_Pe

Net Loss Per Share Net Loss Per Share (Policies)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share Policy	'
	Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 58,129,967 and 38,421,415 shares for the nine months ended September 30, 2014 and 2013, respectively, are excluded from the calculation of diluted net loss per share since their effect is anti-dilutive.

Inventories_Policy

Inventories (Policy)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Policy	'
	The Company uses the lower of first-in, first-out (“FIFO”) cost or market method of accounting for inventory.

Property_and_Equipment_Policie

Property and Equipment (Policies)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]	'
Property, Plant and Equipment, Policy	'
	Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from five to thirty-nine years.

Cash_And_Cash_Equivalents_Poli

Cash And Cash Equivalents (Policies)	9 Months Ended
	Sep. 30, 2014
Cash and Cash Equivalents, at Carrying Value [Abstract]	'
Cash and Cash Equivalents, Policy	'
	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

EquityBased_Compensation_Table

Equity-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Weighted Average Assumptions	'
	The fair values of the options and equity warrants granted in the nine months ended September 30, 2014 and 2013, were estimated based on the following weighted average assumptions:
		Nine Months Ended September 30,
		2014		2013
	Risk-free interest rate	1.66% - 1.72%		0.14% - 1.40%
	Expected dividend yield	—		—
	Expected lives	5 years		1 year to 5 years
	Expected volatility	88.33% - 92.63%		89.73% - 118.22%
	Weighted average grant date fair value for options and equity warrants issued	$0.22 per option/warrant for 955,000 options/warrants		$0.14 per option/warrant for 3,870,000 options/warrants
Stock Option Activity	'
	Stock option for employees' activity during the nine months ended September 30, 2014 is as follows:
	Stock option activity for employees:
		Number of			Weighted		Weighted	Aggregate
		Options			Average		Average	Intrinsic
					Exercise		Remaining	Value
					Price		Contractual
							Term
							(Years)
	Outstanding January 1, 2014	10,611,480			$	1.73	4.92	$	—
	Granted	905,000			0.36		9.67	—
	Forfeited	(367,000	)		1.42		4.22	—
	Outstanding September 30, 2014	11,149,480			$	1.63	4.61	$	—
	Vested and expected to vest September 30, 2014	11,149,480			$	1.63	4.61	$	—
	Exercisable September 30, 2014	10,541,980			$	1.69	4.2	$	—
	905,000 options to purchase shares were granted to employees during the nine months ended September 30, 2014.
	Unvested stock option activity for employees:
		Number of			Weighted		Average		Aggregate
		Options			Average		Remaining		Intrinsic
					Exercise		Contractual		Value
					Price		Term
							(Years)
	Outstanding January 1, 2014	525,000			$	0.29	8.38		$	—
	Granted	905,000			0.36		9.67		—
	Vested	(822,500	)		0.3		9.14		—
	Forfeited	—			—		—		—
	Outstanding September 30, 2014	607,500			$	0.37	8.63		$	—
	Stock option activity for non-employees:
		Number of			Weighted		Weighted		Aggregate
		Options			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term (Years)
	Outstanding January 1, 2014	4,128,432			$	1.48	5.01		$	—
	Granted	50,000			2.6		9.17		—
	Exercised	—			—		—		—
	Forfeited	(368,428	)		2.8		1.93		—
	Outstanding September 30, 2014	3,810,004			$	1.37	4.64		$	—
	Vested and expected to vest September 30, 2014	3,810,004			$	1.37	4.64		$	—
	Exercisable September 30, 2014	3,743,337			$	1.58	4.44		$	—
	50,000 options to purchase shares were granted to non-employees during the nine months ended September 30, 2014.
	Unvested stock option activity for non-employees during the year:
		Number of			Weighted		Weighted		Aggregate
		Options			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term
							(Years)
	Outstanding January 1, 2014	470,833			$	0.25	9.61		$	—
	Options granted	50,000			2.6		9.17		—
	Options vested	(454,166	)		0.28		8.86		—
	Options forfeited	—			—		—		—
	Outstanding September 30, 2014	66,667			$	1.84	9.09		$	—

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventories consist of the following:	(in thousands)
		September 30,		December 31,
		2014		2013
	Inventory work-in-process, January 1	$	—	$	453
	Production	—		5
	Spoilage	—		(458		)
	Inventory work-in-process, end of period	$	—	$	—

Marketable_Securities_Tables

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Available for sale securities	'
	Securities classified as available for sale consisted of:
	30-Sep-14
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair Value			Short-Term			Long Term
		Cost			Unrealized			Unrealized							Investments			Investments
					Gains			Losses
	Mutual Funds	$	16,283		$	—		$	(114	)		$	16,169		$	16,169		$	—
	Totals	$	16,283		$	—		$	(114	)		$	16,169		$	16,169		$	—
	31-Dec-13
	(in thousands)
	Securities	Amortized			Gross			Gross				Fair Value			Short-Term			Long Term
		Cost			Unrealized			Unrealized							Investments			Investments
					Gains			Losses
	Mutual Funds	$	17,505		$	115		$	(229	)		$	17,391		$	17,391		$	—
	Totals	$	17,505		$	115		$	(229	)		$	17,391		$	17,391		$	—
Unrealized losses on securities	'
	Investments with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows:
	30-Sep-14
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number		Values			Losses				Values			Losses			Fair			Unrealized
		in loss															Value			Losses
		position
	Mutual Funds	1		$	9,630		$	(126	)		$	—		$	—		$	9,630		$	(126	)
	Totals	1		$	9,630		$	(126	)		$	—		$	—		$	9,630		$	(126	)
	31-Dec-13
	(in thousands)
				Less Than 12 Months							12 Months or Greater						Totals
	Securities	Total		Fair			Unrealized				Fair			Unrealized			Total			Total
		number		Values			Losses				Values			Losses			Fair			Unrealized
		in loss															Value			Losses
		position
	Mutual Funds	1		$	12,460		$	(229	)		$	—		$	—		$	12,460		$	(229	)
	Totals	1		$	12,460		$	(229	)		$	—		$	—		$	12,460		$	(229	)

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities	'
	Accrued expenses consist of the following:
		(in thousands)
		September 30,		December 31,
		2014		2013
	Compensation	$	1,438	$	378
	Professional fees	141		270
	Other expenses	192		529
	Accrued Alferon production costs	10		51
		$	1,781	$	1,228

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]	'
Property, Plant and Equipment	'
		(in thousands)
		September 30,			December 31,
		2014			2013
	Land, buildings and improvements	$	4,209		$	4,209
	Furniture, fixtures, and equipment	5,256			5,093
	Leasehold improvements	85			85
	Total property and equipment	9,550			9,387
	Less: accumulated depreciation and amortization	(4,834		)	(4,334		)
	Property and equipment, net	$	4,716		$	5,053

Fair_Value_Tables

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Schedule of Assumptions for Fair Value	'
	Fair value at September 30, 2014, was estimated using the following assumptions:
	Underlying price per share	$0.19 - $0.27
	Exercise price per share	$1.31 - $1.65
	Risk-free interest rate	0.06% - 0.23%
	Expected holding period	0.38 - 1.64 yrs.
	Expected volatility	69.74% - 113.56%
	Expected dividend yield	None
Schedule of fair value, assets and liabilities measured on recurring basis	'
	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as of September 30, 2014:
		(in thousands)
		Total			Level 1			Level 2		Level 3
	Assets:
	Marketable Securities	$	16,169		$	16,169		$	—	$	—
	Liabilities:
	Warrants	$	(13	)	$	—		$	—	$	(13	)
Fair Value, Inputs, Level 3 [Member]	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Fair value, liabilities measured on recurring basis	'
	The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows:
		Fair Value of Redeemable
		Warrants
		(in thousands)
		2014			2013
	Balance at January 1	$	14		$	295
	Fair value adjustment at March 31	—			(89		)
	Balance at March 31	14			206
	Fair value adjustment at June 30	(1		)	(102		)
	Balance at June 30	13			104
	Fair value adjustment at September 30	—			(38		)
	Balance at September 30	$	13		$	66

Basis_of_Presentation_Details

Basis of Presentation (Details)	9 Months Ended
	Sep. 30, 2014
	subsidiary
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of domestic subsidiaries (subsidiaries)	3

Net_Loss_Per_Share_Details

Net Loss Per Share (Details)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'
Stock options and warrants excluded from calculation of diluted net loss per share (shares)	58,129,967	38,421,415

EquityBased_Compensation_Valua

Equity-Based Compensation (Valuation Assumptions) (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Method used	'Black-Scholes-Merton	'
Expected dividend yield (percent)	0.00%	0.00%
Expected term	'5 years	'
Options or equity warrants granted in period (shares)	955,000	'
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate (percent)	1.66%	0.14%
Expected term	'	'1 year
Expected volatility (percent)	88.33%	89.73%
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate (percent)	1.72%	1.40%
Expected term	'	'5 years
Expected volatility (percent)	92.63%	118.22%
Weighted Average [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted average grant date fair value per option (usd per share)	0.22	0.14
Weighted average grant date fair value, options issued (shares)	955,000	3,870,000

EquityBased_Compensation_Optio

Equity-Based Compensation (Option Activity) (Details) (USD $)	9 Months Ended			12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
			Employee Vested Options [Member]	Employee Vested Options [Member]	Employee Nonvested Options [Member]	Employee Nonvested Options [Member]	Nonemployee Vested Options [Member]	Nonemployee Vested Options [Member]	Nonemployee Nonvested Options [Member]	Nonemployee Nonvested Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'	'	'	'	'	'	'	'	'
Number of options outstanding (shares)	'	'	10,611,480	'	525,000	'	4,128,432	'	470,833	'
Number of options granted (shares)	'	'	905,000	'	905,000	'	50,000	'	50,000	'
Number of options vested (shares)	'	'	'	'	-822,500	'	'	'	-454,166	'
Number of options exercised (shares)	'	'	'	'	'	'	0	'	'	'
Number of options forfeited (shares)	'	'	-367,000	'	0	'	-368,428	'	0	'
Number of options outstanding (shares)	'	'	11,149,480	10,611,480	607,500	525,000	3,810,004	4,128,432	66,667	470,833
Number of options vested and expected to vest, outstanding (shares)	'	'	11,149,480	'	'	'	3,810,004	'	'	'
Number of options vested and expected to vest, exercisable (shares)	'	'	10,541,980	'	'	'	3,743,337	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'	'	'	'	'	'	'	'	'
Weighted Average Exercise Price, Options Outstanding (usd per share)	'	'	$1.73	'	$0.29	'	$1.48	'	$0.25	'
Weighted Average Exercise Price, Options Granted (usd per share)	'	'	$0.36	'	$0.36	'	$2.60	'	$2.60	'
Weighted Average Exercise Price, Options Exercised (usd per share)	'	'	'	'	'	'	$0	'	'	'
Weighted Average Exercise Price, Options Vested (usd per share)	'	'	'	'	$0.30	'	'	'	$0.28	'
Weighted Average Exercise Price, Options Forfeited (usd per share)	'	'	$1.42	'	$0	'	$2.80	'	$0	'
Weighted Average Exercise Price, Options Outstanding (usd per share)	'	'	$1.63	$1.73	$0.37	$0.29	$1.37	$1.48	$1.84	$0.25
Weighted Average Exercise Price, Options Vested and Expected to Vest, Outstanding (usd per share)	'	'	$1.63	'	'	'	$1.37	'	'	'
Weighted Average Exercise Price, Options Vested and Expected to Vest, Exercisable (usd per share)	'	'	$1.69	'	'	'	$1.58	'	'	'
Share-based Compensation Arrangement By Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Roll Forward]	'	'	'	'	'	'	'	'	'	'
Weighted Average Remaining Contractual Term (Years), Options outstanding	'	'	'4 years 7 months 10 days	'4 years 11 months 1 day	'8 years 7 months 17 days	'8 years 4 months 17 days	'4 years 7 months 21 days	'5 years 0 months 4 days	'9 years 1 month 2 days	'9 years 7 months 10 days
Weighted Average Remaining Contractual Term (Years), Options Granted	'	'	'9 years 8 months 1 day	'	'9 years 8 months 1 day	'	'9 years 2 months 1 day	'	'9 years 2 months 1 day	'
Weighted Average Remaining Contractual Term (Years), Options Vested	'	'	'	'	'9 years 1 month 21 days	'	'	'	'8 years 10 months 10 days	'
Weighted Average Remaining Contractual Term (Years), Options Forfeited	'	'	'4 years 2 months 19 days	'	'	'	'1 year 11 months 5 days	'	'	'
Weighted Average Remaining Contractual Term (Years), Options outstanding	'	'	'4 years 7 months 10 days	'4 years 11 months 1 day	'8 years 7 months 17 days	'8 years 4 months 17 days	'4 years 7 months 21 days	'5 years 0 months 4 days	'9 years 1 month 2 days	'9 years 7 months 10 days
Weighted Average Remaining Contractual Term (Years), Options vested and expected to vest	'	'	'4 years 7 months 10 days	'	'	'	'4 years 7 months 21 days	'	'	'
Weighted Average Remaining Contractual Term (Years), Options exercisable	'	'	'4 years 2 months 12 days	'	'	'	'4 years 5 months 9 days	'	'	'
Share-based Compensation Arrangement By Share-based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward]	'	'	'	'	'	'	'	'	'	'
Aggregate Intrinsic Value, Options Outstanding	'	'	$0	'	$0	'	$0	'	$0	'
Aggregate Intrinsic Value, Options Granted	'	'	0	'	0	'	0	'	0	'
Aggregate Intrinsic Value, Options Exercised	'	'	'	'	'	'	0	'	'	'
Aggregate Intrinsic Value, Options Vested	'	'	'	'	0	'	'	'	0	'
Aggregate Intrinsic Value, Options Forfeited	'	'	0	'	0	'	0	'	0	'
Aggregate Intrinsic Value, Options Outstanding	'	'	0	0	0	0	0	0	0	0
Aggregate Intrinsic Value, Options Vested and Expected to Vest, Outstanding	'	'	0	'	'	'	0	'	'	'
Aggregate Intrinsic Value, Options Vested and Expected to Vest, Exercisable	'	'	0	'	'	'	0	'	'	'
Stock issued during period, value	260	292	'	'	'	'	'	'	'	'
Total compensation cost not yet recognized	$301	$492	'	'	'	'	'	'	'	'

Inventories_Details

Inventories (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Inventory Work-in-Process [Roll Forward]	'	'
Inventory, work-in-process, beginning of period	$0	$453
Production	0	5
Spoilage	0	-458
Inventory work-in-process, end of period	$0	$0

Marketable_Securities_Availabl

Marketable Securities (Available for Sale Securities) (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$16,283	$17,505
Gross Unrealized Gains	0	115
Gross Unrealized Losses	-114	-229
Fair Value	16,169	17,391
Short-Term Investments	16,169	17,391
Long Term Investments	0	0
Mutual Funds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	16,283	17,505
Gross Unrealized Gains	0	115
Gross Unrealized Losses	-114	-229
Fair Value	16,169	17,391
Short-Term Investments	16,169	17,391
Long Term Investments	$0	$0

Marketable_Securities_Details

Marketable Securities (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
	investment	investment
Schedule of Available-for-sale Securities [Line Items]	'	'
Total number in loss position (investments)	1	1
Less than twelve months - fair values	$9,630	$12,460
Less than twelve months - unrealized losses	-126	-229
Twelve months or greater - fair values	0	0
Twelve months or greater - unrealized losses	0	0
Total Fair Value	9,630	12,460
Total Unrealized Losses	-126	-229
Mutual Funds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Total number in loss position (investments)	1	1
Less than twelve months - fair values	9,630	12,460
Less than twelve months - unrealized losses	-126	-229
Twelve months or greater - fair values	0	0
Twelve months or greater - unrealized losses	0	0
Total Fair Value	9,630	12,460
Total Unrealized Losses	($126)	($229)
Unrestricted Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Investments with other than temporary impairments (investments)	0	'

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Compensation	$1,438	$378
Professional fees	141	270
Other expenses	192	529
Accrued Alferon production costs	10	51
Total Accrued Expenses	$1,781	$1,228

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended								9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014
			Land, buildings and improvements [Member]	Land, buildings and improvements [Member]	Furniture, fixtures, and equipment[Member]	Furniture, fixtures, and equipment[Member]	Leasehold improvements [Member]	Leasehold improvements [Member]	Minimum [Member]	Maximum [Member]
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'
Total property and equipment	$9,387	$9,550	$4,209	$4,209	$5,256	$5,093	$85	$85	'	'
Less: accumulated depreciation and amortization	-4,334	-4,834	'	'	'	'	'	'	'	'
Property and equipment, net	5,053	4,716	'	'	'	'	'	'	'	'
Useful life	'	'	'	'	'	'	'	'	'5 years	'39 years
Construction in progress	7,046	7,269	'	'	'	'	'	'	'	'
Capitalized interest charges	$143	'	'	'	'	'	'	'	'	'

Margin_Account_Loan_Details

Margin Account Loan (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]	'	'
Line of credit facility initiation date	26-Jul-11	'
Interest rate during period (percent)	2.50%	'
Reduction in Wells Fargo base rate (percent)	2.75%	'
Margin account loan liability	$0	$0
Increase in accrued interest	'	$130,000

Stockholders_Equity_Details

Stockholders' Equity (Details) (Equity Incentive Plan of 2009 [Member])	9 Months Ended
	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Date established	24-Jun-09
Number of shares authorized (shares)	15,000,000
Consultants [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Award requisite service period	'10 years
Number of options granted (shares)	905,000

Stockholders_Equity_Equity_Dis

Stockholders' Equity (Equity Distribution Agreement) (Details) (Maxim 2012 Agreement [Member], USD $)	0 Months Ended	9 Months Ended	0 Months Ended
	Jul. 23, 2012	Sep. 30, 2014	Oct. 05, 2012	Oct. 05, 2012	Sep. 14, 2012	Sep. 14, 2012
			October 5, 2012 Prospectus Supplement Increased Offering [Member]	December 23, 2013 Prospectus Supplement Increased Offering [Member]	Minimum [Member]	Maximum [Member]
					September 14, 2012 Prospectus Supplement Increased Offering [Member]	September 14, 2012 Prospectus Supplement Increased Offering [Member]
Class of Stock [Line Items]	'	'	'	'	'	'
Maximum dollar amount of shares under the EDA	$75,000,000	'	'	'	'	'
Fixed commission rate for gross proceeds $10,000,000 or less (percent)	4.00%	'	'	'	'	'
Gross proceeds from common stock, threshold	10,000,000	'	'	'	'	'
Fixed commission rate for gross proceeds in excess of $10,000,000 (percent)	3.00%	'	'	'	'	'
Number of shares to be sold under the equity distribution agreement	'	'	40,000,000	90,000,000	12,000,000	20,000,000
Number of shares sold under equity distribution agreement	'	24,894,781	'	'	'	'
Cash proceeds from shares sold under equity distribution agreement	'	9,763,000	'	'	'	'
Commissions paid on shares sold under equity distribution agreement	'	$302,000	'	'	'	'

Fair_Value_Fair_Value_Assumpti

Fair Value (Fair Value Assumptions) (Details) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
		Minimum [Member]	Maximum [Member]	Warrant [Member]	Warrant [Member]	Carrying Amount [Member]	Carrying Amount [Member]
						Warrant [Member]	Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'	'
Underlying price per share (usd per share)	'	$0.19	$0.27	'	'	'	'
Exercise price per share (usd per share)	'	$1.31	$1.65	'	'	'	'
Risk-free interest rate (percent)	'	0.06%	0.23%	'	'	'	'
Expected holding period	'	'0 years 4 months 17 days	'1 year 7 months 19 days	'	'	'	'
Expected volatility (percent)	'	69.74%	113.56%	'	'	'	'
Expected dividend yield (usd per share)	$0	'	'	'	'	'	'
Liabilities, fair value disclosure	'	'	'	$13	$14	$13	$14

Fair_Value_Assets_and_Liabilit

Fair Value (Assets and Liabilities Measured on a Recurring Basis) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable securities	$16,169	$17,391
Redeemable warrants	-13	-14
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable securities	16,169	'
Redeemable warrants	0	'
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable securities	0	'
Redeemable warrants	0	'
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable securities	0	'
Redeemable warrants	($13)	'

Fair_Value_Fair_Value_Changes_

Fair Value Fair Value (Changes in Level 3 Liabilities) (Details) (Warrant [Member], USD $)

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

In Thousands, unless otherwise specified

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Changes Measurement [Member]

Changes Measurement [Member]

Changes Measurement [Member]

Changes Measurement [Member]

Changes Measurement [Member]

Changes Measurement [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, beginning

$13

$13

$14

$14

$66

$104

$206

$295

'

'

'

'

'

'

Fair value adjustment

'

'

'

'

'

'

'

'

0

-1

0

-38

-102

-89

Balance, ending

$13

$13

$14

$14

$66

$104

$206

$295

'

'

'

'

'

'

Funds_Received_From_Sale_Of_In1

Funds Received From Sale Of Income Tax Net Operating Losses (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended				1 Months Ended
	Feb. 28, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2013	Feb. 28, 2014	Dec. 31, 2013
						Internal Revenue Service (IRS) [Member]	Pennsylvania [Member]	New Jersey [Member]	New Jersey [Member]
Operating Loss Carryforwards [Line Items]	'	'	'	'	'	'	'	'	'
Operating loss carryforwards	'	'	'	'	'	$134,000,000	$37,000,000	'	$25,000,000
Operating loss carryforwards, amount of NOL carryforwards sold	'	'	'	'	'	'	'	13,900,000	'
Funds received from sale of income tax net operating losses	$1,126,000	$0	$0	$1,126,000	$686,000	'	'	'	'

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event [Member], USD $)	1 Months Ended
	Oct. 31, 2014
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Purchase commitment with a contract manufacturer	$700,000